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Background 
 
Bloodstream infections are the most common form of infections. Mortality is high, between 
15 and 35%1-5. As a result, bloodstream infections in the top 7 of most common causes of 
death, and account for approximately 157.000 deaths in Europe annually6. The incidence is 
rising, and as a result, the total number of deaths attributed to bloodstream infections has 
risen7,8.  
Treatment of bloodstream infections has two pillars: symptomatic treatment, by fluid 
resuscitation, and treatment of the cause of infection with antibiotics. Empirically one or 
more broad-spectrum antibiotics are administered, but since no ‘one size fits all’ antibiotic 
exists, therapy will likely be too narrow or too broad. In the past years antibiotic resistance 
has increased substantially in Gram-negative bacteria9. Thus, empirical therapy is more likely 
to be inadequate, which is associated with increased mortality. It is therefore increasingly 
important to know the antibiotic susceptibility pattern of the causative microorganism. Data 
on the antibiotic susceptibility of a microorganism currently are not available until at least 2 
days after initiation of antibiotic therapy, since a positive blood culture requires more than 
one working day to grow and results of antibiotic susceptibility testing will not become 
available until another day later. More rapid identification and antibiotic susceptibility testing 
potentially enable earlier switching to adequate therapy and reduce the use of broad-
spectrum therapy. 
 
Conclusions of this thesis 
 
In this thesis more rapid methods for ID and AST are presented, combining techniques and 
devices that are already available in the majority of microbiological labs (Chapters 2,3 en 4). 
Furthermore, it was shown that by using these methods, results of ID and AST are available 
significantly earlier than standard-of-care methods (Chapter 5). Also, significantly more 
patients received appropriate therapy on the same working day the blood culture had 
signalled positive, due to the rapid tests. However, due to lack of implementation of test 
results this did not result in a reduction of total time too-broad or inadequate therapy was 
used (Chapter 5). In addition it was shown that MALDI-TOF MS can be a useful tool in 
discerning blood culture contamination from true bloodstream infection, possibly leading to 
less use of antibiotic therapy (Chapter 6). 
 
Target groups 
 
The methods and results presented in this thesis are important for many groups of 
professionals involved in the healthcare system. 
For clinical microbiologists and molecular medical microbiologists, the methods presented in 
this thesis offer new approaches to the diagnosis of bloodstream infections. It was shown that 
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more rapid bacterial ID and AST are possible, using techniques that they very likely already 
have available. The DNA-extraction techniques used in this thesis were very simple to 
perform, cheap and reliable, showing that PCR-assays on positive blood cultures can be 
performed without the need of expensive and extensive DNA-extraction kits. Additionally, it 
was shown that MALDI-TOF MS, which nowadays has become standard equipment in almost 
every lab, can help in determining whether a blood culture was contaminated or not. Such 
test results may help clinicians in deciding whether or not to prescribe antibiotic therapy. 
For clinical microbiologists, as well as for infectious diseases specialists, the thesis shows how 
important implementation of test results is, and that focus on successful implementation 
strategies is essential in gaining full benefit from technical advances.  
 
Ultimately, and most importantly, the results of the thesis are important for the patient. It 
shows that rapid ID and AST did not result in an overall time reduction of administering 
inadequate or too broad-spectrum antibiotic therapy. However, for a small group of patients 
it did result in significantly earlier appropriate antibiotic therapy. When implementation rates 
are higher, earlier overall appropriate therapy may be achieved with these new techniques. 
Earlier adequate antibiotic therapy and early recognition of a clinically relevant blood culture 
can improve the patients’ prognosis10,11. Narrowing down antibiotic therapy earlier can also 
be beneficial for the patient, since using less antibiotics means a lower risk of side effects, and 
more narrow-spectrum antibiotics carry a lower risk of Clostridium difficile infections12,13.  
The benefits of narrowing down antibiotic therapy earlier will be more profound on the 
population level, since it reduces the total use of antibiotics. The more antibiotics are being 
used, the higher the levels of antibiotic resistance are14. In some countries, carbapenem 
resistant Enterobacteriaceae (CRE) and MRSA have already become endemic, making 
treatment of infections with these bacteria much more difficult, and sometimes even 
impossible15,16. In the Netherlands, this is not (yet) the case, infections with CRE and MRSA 
are still rare. However, infections with ESBL-producing Enterobacteriaceae seem to become 
more and more common9, and outbreaks of infections caused by CRE have already been 
described15. These data indicate that in the future we may also face more serious resistance 
problems if no preventive measures are implemented. Reducing the use of antibiotics could 
result in lower rates of development and selection of resistant microorganisms, and more 
rapid ID and AST could aid in the reduction of antibiotic use, if properly implemented. 
 
Financial implications 
 
In 2014, expenses on antibiotics in the Netherlands were 35,6 million euros, which was an 
increase of 0.6 million euros when compared to 2011. The total number of Defined Daily 
Doses (DDD) of antibiotics had decreased with 6% between 2011 and 2014, and prices of 
most antibiotics have also decreased over the past years17. That the total expenses on 
antibiotics have risen nevertheless can be attributed to the increased use of more expensive 
broad-spectrum antibiotics, such as 3rd generation cefalosporins, linezolid, vancomycin and 
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meropenem9,17. Prices for these antibiotics range from 14.82 euros/dose (for vancomycin) to 
60.84 euros per dose (linezolid), whereas the more frequently used amoxicillin, amoxicillin-
clavulanate and cefuroxime are relatively inexpensive, ranging from 1.37 to 5.04 
euros/dose9,18.  
Earlier results of ID and AST can lead to an earlier switch to a more narrow-spectrum 
antibiotic and thus a reduction of use of these expensive broad-spectrum antibiotics. 
However, as a result of the relatively low antibiotic resistance rates in the Netherlands, 
expensive broad-spectrum antibiotics are used relatively infrequent. The most widely used 
broad-spectrum antibiotics are 3rd generation cefalosporins, with 5 DDD per 100 patient-days, 
on a total amount of antibiotics used in hospitals of 74.7 DDD per 100 patient-days (6.7%)9. 
But the other expensive very broad-spectrum antibiotics combined represent only a very 
small fraction of the total of amount of antibiotics used in hospitals, with 3.3 DDD per 100 
patient-days (4.4%)9. Although antibiotic costs are only a small fraction (<1%) of the total 
costs of pharmaceuticals in the Netherlands, which are >4 billion euros17,19, earlier ID and AST 
can result in a reduction of direct costs of antibiotics. 
 
But earlier adequate therapy results in a better prognosis for the patient10,11, which results in 
a reduction in health care costs, for instance by shortening length of hospital stay. And since 
reducing the amount of antibiotics used could reduce antibiotic resistance development, it 
would also reduce the additional healthcare costs that are generated by infections with 
antibiotic resistant microorganisms, which are estimated to be 1,5 billion euros per year in 
Europe20 and even 20 billion dollars per year in the USA21. 
 
Future references 
 
The assays presented in this thesis can easily be adjusted, by adding or replacing 
microorganisms or antibiotics. Automation of the tests potentially allows for more rapid 
assays, reduced hands-on time, higher throughput and lower costs. And in the future, more 
rapid PCR techniques could be used to reduce PCR time. 
 
The assays could be combined with other measures to reduce time-to-results, such as 
extended laboratory opening hours and improved hospital and laboratory logistics. 
Implementation of test results can be improved by the formation of Antibiotic Stewardship 
Teams. The rapid assays could be of assistance in their goal of earlier adequate therapy and 
reduction of unnecessary broad-spectrum antibiotic therapy. 
 
Possibly, currently available methods are not sufficient in reducing broad-spectrum antibiotic 
use and time to appropriate therapy. Development of more rapid techniques is required, 
especially since studies have shown that the rate of antibiotic switching is inversely related to 
the time to results22,23. Since the incubation of the blood culture bottle is the most time 
consuming step, this would be the most likely target for improvement. It is possible to reduce 
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incubation time and still obtain reliable ID results, as was shown by Loonen et al. in 201224. 
Ideally, the blood culture step can be eliminated completely, by using PCR- and sequencing 
techniques that can be used directly on blood. However, the possibility that, in the near 
future, these techniques can replace culture based techniques is low, for reasons described in 
Chapter 1. At this moment, most effort is invested in new, more rapid assays and techniques 
that are performed on positive blood cultures or subcultures on agar.  
 
Additionally, better techniques and tools to discern contaminated blood cultures from those 
representing true bloodstream infection are needed with the goal to reduce, or, ideally, 
eliminate blood culture contamination. 
 
It is important to limit the costs of newly developed techniques, because although a more 
rapid diagnosis can save money and lives, healthcare costs continue to rise and more patients 
will require diagnosis and treatment of bloodstream infections, since their incidence is rising. 
Cost effectiveness studies should thus be part of the introduction of new tests. 
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